Evidence map›Paper›PMID 30932697›Full record

ArticleAIDS patient care and STDs2019

Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.

Emily A Krogstad, Elizabeth T Montgomery, Millicent Atujuna, Alexandra M Minnis, Shannon O'Rourke, Khatija Ahmed, Linda-Gail Bekker, Ariane van der Straten

Abstract read
In one paragraph

Article in AIDS patient care and STDs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emily A Krogstad1 Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Elizabeth T Montgomery3 RTI International, Women's Global Health Imperative, Los Angeles, California.
Millicent Atujuna1 Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Alexandra M Minnis2 RTI International, Women's Global Health Imperative, San Francisco, California.
Shannon O'Rourke2 RTI International, Women's Global Health Imperative, San Francisco, California.
Khatija Ahmed4 Setshaba Research Center, Soshanguve, South Africa.
Linda-Gail Bekker1 Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Ariane van der Straten2 RTI International, Women's Global Health Imperative, San Francisco, California.

Funding

End-user research to optimize adherence to injectable HIV prevention approachesR01MH105262 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI MONTGOMERY, ELIZABETH TRASK · 2015 to 2017
$1.8M
NIMH NIH HHS R01 MH105262PEPFAR
6 · The paper itself

Abstract

Implants are in the pre-clinical stage for long-acting HIV pre-exposure prophylaxis (PrEP), with an opportunity to solicit end-users' feedback early in development. Health care providers (HCPs) have been key gatekeepers for contraceptive implant uptake, and uniquely understand both technical considerations and the social context of use. Given their influential role, we gathered South African HCP perspectives on contraceptive implant implementation and features of PrEP implant prototypes that may influence future provider and patient acceptability. We conducted in-depth interviews with 30 HCPs (20 nurses and 10 doctors) in Cape Town and Soshanguve, South Africa. Interviews were conducted by a bioengineer and later transcribed, coded, and analyzed for key themes. HCPs described health system barriers such as understaffed clinics and inadequate training on contraceptive implant removal as major influences to their PrEP implant design preferences. They preferred a PrEP implant that is long lasting (>6 months) to minimize patient-clinic interactions, biodegradable to avoid need for removal, and flexible (but still palpable in case of removal). Commenting on negative experiences with contraceptive implant rollout, they recommended prioritizing both HCP and community education on the PrEP implant, with emphasis on expected side effects, and planning ahead for adequate training of HCPs before rollout. Challenges experienced with past contraceptive implant rollout may taint perspectives on future PrEP implants and must be carefully considered during product development and planning for clinical studies. Particular consideration should be given to the health system context of future distribution, including staff who would be providing and monitoring implants.

Indexed as

Drug ImplantsAdultAnti-HIV AgentsBlack PeopleFemaleHealth PersonnelHIV InfectionsHumansInterviews as TopicMaleMiddle AgedPre-Exposure ProphylaxisSouth AfricaAnti-HIV AgentsDrug Implantscontraceptivehealth care providersHIV pre-exposure prophylaxisimplantproduct developmentSouth Africa

Identifiers

PMID30932697
PMCPMC6459268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.